The addition of paclitaxel to doxorubicin and cisplatin and volume-directed radiation does not improve overall survival (OS) or long-term recurrence-free survival (RFS) in advanced endometrial cancer (EC): A randomized phase III NRG/Gynecologic Oncology Group (GOG) study

Abstract

Conflicts of interest Dr. Nick Spirtos receives money from a grant to the Women's Cancer Center of Nevada, Inc. and also support for travel to meetings for the study or other purposes. He also receives royalties paid to him regarding Wiley -textbook authorship. Dr. Danielle Enserro receives money to her institution from NCI for Cooperative Group/NCTN Grant Funding for all aspects of this trial, including travel to Group meetings; statistical analysis, study monitoring, etc. She also receives monies from a NCTN Group Funding Grant through NCI, as well as monies from the GOG Foundation, Inc. Dr. David Cella received money from GOG/NRG for support for travel to meetings for the study or other purposes. Dr. Robert Morris served as a consultant for Clovis Oncology and Janssen. Dr. David Miller served as a consultant for Tesaro, Janssen, Clovis and Genentech. His institution also received grant funding through Advenchen, Takeda, Tesaro and Xenetic. He also received monies from Genentech and Clovis for payment for lectures, including service on speakers' bureaus.

Reporting of tobacco use and tobacco-related analyses in cancer cooperative group clinical trials: a systematic scoping review

“…A total of 91 studies representing 90 trials met the inclusion criteria and were included in the final analyses. 23 , 24 , 25 , 26 , 27 , 28 , 29 , 30 , 31 , 32 , 33 , 34 , 35 , 36 , 37 , 38 , 39 , 40 , 41 , 42 , 43 , 44 , 45 , 46 , 47 , 48 , 49 , 50 , 51 , 52 , 53 , 54 , 55 , 56 , 57 , 58 , 59 , 60 , 61 , 62 , 63 , 64 , 65 , 66 , 67 , 68 , 69 , 70 , 71 , 72 , 73 , 74 , 75 , 76 , 77 , 78 , 79 , 80 , 81 , 82 , 83 , 84 , 85 , 86 , 87 , 88 , 89 , 90 , ...…”

Uterine Neoplasms, Version 1.2023, NCCN Clinical Practice Guidelines in Oncology

“…The 3-drug regimen was associated with improved survival (15 vs 12 months; P,.04) but with significantly increased toxicity (ie, peripheral neuropathy); therefore, it is not widely used. [266][267][268] These regimens are recommended as second-line options in the NCCN Guidelines, because most panel members feel that carboplatin/ paclitaxel is a less toxic and preferred first-line option. The response rates with other multiagent chemotherapies have ranged from 31% to 81%, but with relatively short durations.…”

Landscape of Endometrial Cancer: Molecular Mechanisms, Biomarkers, and Target Therapy

“…These drugs belong to different categories: taxane, platinum-based, anthracycline, and alkylating agent chemotherapy drugs. These chemotherapy drugs interfere with the growth and division of cancer cells by damaging the DNA of cancer cells and may be used alone or in various combinations [ 123 , 124 ]. The dosage and specific regimen of these chemotherapeutic drugs depend on the stage and characteristics of the endometrial cancer.…”